Posts by: Alice Melão

News

The Pulmonary Fibrosis Foundation‘s (PFF) inaugural walk in Chicago on Sept. 9 to kick off Pulmonary Fibrosis Awareness Month far exceeded expectations, drawing over 1,000 participants and helping to raise ... Read more

October 11, 2017October 11, 2017

Potential Oral Asthma Therapy Enters Phase 1 Clinical Development, OncoArendi Says

Asthma, News

Germany’s top regulatory agency has approved a Phase 1 clinical study in healthy volunteers of OATD-01, an investigative asthma drug developed by Poland’s OncoArendi Therapeutics. The approval by Germany’s Federal Institute for ... Read more

October 4, 2017October 4, 2017

Europe Approves Tecentriq Therapy for Advanced or Metastatic NSCLC

Lung Cancer, News

Patients in the European Union who have advanced or metastatic non-small cell lung cancer (NSCLC) now can be treated with Roche’s Tecentriq (atezolizumab). According to the European Commission marketing authorization, ... Read more

September 29, 2017September 29, 2017

Phase 2 Trial Shows Patara’s PA101 May Reduce Chronic Cough in IPF Patients

News

Phase 2 clinical trial data demonstrated that Patara Pharma‘s investigative anti-inflammatory drug PA101 has the potential to significantly reduce chronic coughing in patients with idiopathic pulmonary fibrosis (IPF). This finding ... Read more

September 19, 2017September 19, 2017

Tezepelumab Reduces Exacerbation Rates in Patients with Severe Asthma, Trial Results Show

Asthma, News

Patients with severe and uncontrolled asthma who took tezepelumab had significantly lower annual asthma exacerbation rates than those on placebo, according to the latest results of the PATHWAY Phase 2b trial. ... Read more

September 14, 2017September 14, 2017

Synairgen and Pharmaxis’ Fibrosis Therapy Candidate Is Heading for Phase 1 Clinical Trial

Idiopathic Pulmonary Fibrosis, News

A potential pulmonary fibrosis therapy that Synairgen and Pharmaxis have been working on is heading for a Phase 1 clinical trial. The two created PXS-5382A as a treatment for idiopathic pulmonary fibrosis (IPF) and other ... Read more

September 13, 2017September 13, 2017

INJOURNEY Trial Data Shows Ofev-Esbriet Combo Is Safe and IPF Patients Tolerate It Well

Idiopathic Pulmonary Fibrosis, News

A combination of Boehringer Ingelheim‘s Ofev (nintedanib) and Genentech’s Esbriet (pirfenidone) as a treatment for idiopathic pulmonary fibrosis (IPF) was safe and well tolerated, according to the latest data from the Phase 4 INJOURNEY trial. ... Read more

September 7, 2017September 7, 2017

Working Lung Model with Intact Vasculature Likely to Aid Research, Lung Transplants

Idiopathic Pulmonary Fibrosis, News

Researchers at Columbia University have found a way to bioengineer a “working” lung — a very complex structure — with a viable and intact blood vessel network that can support studies of ... Read more

September 5, 2017September 5, 2017

SteadyMed’s NDA for Trevyent to Treat PAH Refused by FDA; More Information Needed

Pulmonary Hypertension

The U.S. Food and Drug Administration rejected SteadyMed’s new drug application (NDA) for Trevyent (treprostinil), a treatment for pulmonary arterial hypertension (PAH). According to the FDA’s Refusal to File letter, the ... Read more

August 31, 2017August 31, 2017

Protein Linked to Fibrosis Progression Will Be Focus of Start-up’s Drive for Anti-fibrotic Therapy

Idiopathic Pulmonary Fibrosis, News

Researchers in Singapore have found that inhibiting a protein called interleukin-11, or IL-11, can block fibrosis progression in mice. Enleofen Bio, a recently founded biotechnology start-up company, will try to move this finding ... Read more